deaths from tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial For Obesity and HFpEF, Tirzepatide

Matire premire trace

Activation of GLP-1 Rs triggers glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and promotion of satiety (Kim and Egan, 2008

BMI criteria: The patient has a baseline body mass index (BMI) greater than or equal to 35 kg/m 2

No validated PHQ-2 or PHQ-9 , no dedicated eating-disorder screen, no blood pressure or resting heart rate , no diet history beyond the single 3-option lifestyle self-rating, no exercise history , no broader comorbidity multi-select for hypertension, sleep apnea, NAFLD, PCOS, or GERD, no AUDIT-C -style alcohol quantity-frequency questions, no recreational drug naming (cocaine, opioids, kratom, methamphetamine, cannabis are not asked separately), no pregnancy or breastfeeding screen, no cardiac sudden-death family history , no MEN-2 named separately , no ID upload , and no phone OTP

Multiple medication formats

Lose 10 kilograms, and your body is pushing you to eat 820 extra calories daily